NCT05387369 A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
| NCT ID | NCT05387369 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Huashan Hospital |
| Condition | COVID-19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2022-03-21 |
| Primary Completion | 2023-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2022-03-21 with a primary completion date of 2023-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
Eligibility Criteria
Inclusion Criteria: * Participants who have a positive SARS-CoV-2 test result; * Participants who have one or more mild or moderate COVID-19 symptoms. Exclusion Criteria: * No specific exclusion criteria in this real world study.
Contact & Investigator
Feng Sun, MD
PRINCIPAL INVESTIGATOR
Huashan Hospital affliatied to Fudan University
Frequently Asked Questions
Who can join the NCT05387369 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying COVID-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05387369 currently recruiting?
Yes, NCT05387369 is actively recruiting participants. Contact the research team at aaronsf1125@126.com for enrollment information.
Where is the NCT05387369 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05387369 clinical trial?
NCT05387369 is sponsored by Huashan Hospital. The principal investigator is Feng Sun, MD at Huashan Hospital affliatied to Fudan University. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.